A Molecular Take on Malignant Rhabdoid Tumors

Ming Tang; Roel G W Verhaak

doi:10.1016/j.trecan.2016.04.003

A Molecular Take on Malignant Rhabdoid Tumors

Trends Cancer. 2016 May;2(5):217-218. doi: 10.1016/j.trecan.2016.04.003. Epub 2016 Apr 28.

Authors

Ming Tang¹, Roel G W Verhaak²

Affiliations

¹ Department of Genomic Medicine, UT MD Anderson Cancer Center, Houston, TX 77030, USA.
² Department of Genomic Medicine, UT MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: rverhaak@mdanderson.org.

PMID: 28741508
DOI: 10.1016/j.trecan.2016.04.003

Abstract

The molecular basis for the clinical heterogeneity observed in patients with malignant rhabdoid tumors is unknown. Recently, two reports revealed molecular intertumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs) using genomic, transcriptomic, and epigenomic profiling. Distinct molecular subgroups were identified and new therapeutic targets were revealed.

Keywords: malignant rhabdoid tumors; molecular analysis; pediatric cancer; sequencing.

MeSH terms

Genetic Heterogeneity
Humans
Rhabdoid Tumor / genetics*